Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262594 · ClinicalTrials.gov registry record · Phase 3
Lemborexant Treatment of Insomnia Linked to Epilepsy
A Phase 3 study of Epilepsy and Sleep, sponsored by University of Manitoba.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 2
- Study locations
NCT06262594 is a Phase 3 study of Epilepsy and Sleep that is actively recruiting participants, run by University of Manitoba. The registered enrollment target is 26 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06262594, a Phase 3 study of Epilepsy and Sleep, is actively recruiting participants, sponsored by University of Manitoba.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
Interventions
- DRUG Placebo
- DRUG Lemborexant
Study Locations (2)
North Carolina
- Duke University - Durham
Manitoba
- Health Sciences Centre - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2027-04-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262594
The ClinicalTrials.gov registry entry for NCT06262594 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is University of Manitoba, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06262594 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Manitoba.
Frequently Asked Questions
What is clinical trial NCT06262594 about?
NCT06262594 is a clinical study titled "Lemborexant Treatment of Insomnia Linked to Epilepsy". The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.
What is the current status of trial NCT06262594?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2024-10-29. Estimated completion is 2027-04-18.
What conditions does trial NCT06262594 study?
This clinical trial studies the following conditions: Epilepsy, Sleep.
What interventions are being tested in trial NCT06262594?
The interventions under investigation include: Placebo (DRUG), Lemborexant (DRUG).
Who is sponsoring clinical trial NCT06262594?
This trial is sponsored by University of Manitoba, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262594 being conducted?
This trial has 2 study locations across North Carolina, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
IV Lacosamide: The Safety of Intravenous Lacosamide
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.